Skip to main content

and
  1. No Access

    Article

    Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection

    Until recently, interferon-free anti-hepatitis C virus (HCV) therapy for genotype 2 (GT2) HCV-infected hemodialysis patients was an unfulfilled medical need. Recent clinical trials of glecaprevir and pibrentas...

    Goki Suda, Chitomi Hasebe, Masami Abe, Masayuki Kurosaki in Journal of Gastroenterology (2019)

  2. No Access

    Article

    Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection

    The prevalence of hepatitis C virus (HCV) infection in hemodialysis patients is high and results in a poor prognosis. Thus, safer and more effective treatment regimens are required. In this prospective multice...

    Goki Suda, Masayuki Kurosaki, Jun Itakura, Namiki Izumi in Journal of Gastroenterology (2019)

  3. No Access

    Article

    Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group

    We aimed to describe the real-world efficacy and safety of combination therapy with ledipasvir and sofosbuvir (LDV/SOF) for chronic hepatitis C virus (HCV) genotype 1 (GT1) infection.

    Keiji Tsuji, Masayuki Kurosaki, Jun Itakura, Nami Mori in Journal of Gastroenterology (2018)

  4. No Access

    Article

    Importance of cytotoxic T lymphocytes in the rejection of transplanted hepatocellular carcinoma

    Fischer rats became resistant to syngeneic hepatocellular carcinoma (FAA-HTC1) cells on repeated sensitization with mitomycin C-treated FAA-HTC1 cells. In contrast, FAA-HTC1 cells injected into the liver kille...

    Hironobu Kohda, Chihiro Sekiya, Yoshihiro Torimoto in Journal of Gastroenterology (1994)